



3

1632  
1632

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Applicant: **Young et al.**

Art Unit No.: **1632**

Application No.: **10/081,400**

Examiner: **Joseph T. Voitach**

Filed: **February 20, 2002**

For: **ERYTHROPOIETIN ANALOG-HUMAN SERUM ALBUMIN FUSION**

Attorney Docket Number: **GTC-6D**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

**STATUS INQUIRY**


Dear Sir:

Applicant respectfully inquires as to the status of the above application. The application was filed on February 20, 2002. Per the office action issued September 19, 2005, the application's last known status was "*application is in condition for allowance except for formal matters, prosecution on the merits is closed in accordance with the practice under Ex parte Quayle, 1935 C.D. 11, 453 O.G. 213.*" On December 22, 2005 Applicants filed a Response to Notice of Non-Compliant Amendment for purposes of correcting the CRF relative to this application and correcting SEQ ID No. 3 in the Sequence Listing. Applicant's prior response of September 29, 2005 addressed and corrected other formal matters regarding sequence compliance. Applicant's request a status update with regard to receipt of the Notice of Allowance for allowed claims 53-72.

Respectfully submitted,


3/8/2006  
Date

By:

  
Byron V. Olsen, Attorney for Applicants  
Registration Number 42,960  
GTC Biotherapeutics, Inc.  
175 Crossing Boulevard, Suite 410  
Framingham, MA 01702  
Phone: 508-370-5150 Fax: 508-370-3797

**CERTIFICATE OF MAILING BY FIRST CLASS MAIL**

I hereby certify that under 37 CFR §1.8(a) that this correspondence is being deposited on March 7, 2006 with the United States Postal Service as first class mail with sufficient postage in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

  
Dawn C. Greenaway